Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
July 18, 2014
Cell Reports

The findings presented in this manuscript establish CTCF as a prominent tumor-suppressor gene and point to CTCF-mediated epigenetic stability as a major barrier to neoplastic progression.

CTD²
July 17, 2014
Cell

Researchers elucidate endogenous barriers limiting the process of reprogramming somatic cells to induced pluripotent stem cells by systematically dissecting human cellular reprogramming.

CTD²
July 10, 2014
CNS Oncology

Researchers discuss the development of effective targeted therapy to manage Group 3 medulloblastomas by targeting α5-GABA-A receptor.

CTD²
July 08, 2014
Cell

The transcriptional coactivator YAP1 rescued cell viability in KRAS-dependent cells upon suppression of KRAS and was required for KRAS-induced cell transformation. 

CTD²
July 03, 2014
Blood

Investigators find that acute myeloid leukemias with MLL fusions are dependent on CDK6, offering a therapeutic strategy.

CTD²
July 01, 2014
Nature Medicine

BET proteins are critical regulators of the Hedgehog pathway, suggesting that BET inhibitors may be used to treat Hedgehog-driven tumors.

CTD²
June 27, 2014
Nucleic Acids Research

Authors develop a computational approach for automated quantitation of off-target effects in RNAi screening data sets.

CTD²
June 20, 2014
Methods in Molecular Biology

Researchers present methods which are specifically designed to handle cancer-related copy-number profiles.

CTD²
June 15, 2014
Cancer Research

In an effort to identify biomarkers of recurrence for Prostate cancer, researchers performed global RNA sequencing on 106 formalin-fixed, paraffin-embedded prostatectomy samples from 100 patients at three independent sites, defining a 24-gene signature panel.

CTD²
May 29, 2014
Nature Communications

Researchers use reverse-phase protein arrays to study the proteome and compare it to the genomic and transcriptome analysis of 11 TCGA pan-cancer diseases.

Pages

CSVXML